KDD68907
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
CAS: 1622140-49-1
Systemic immune response to a CD40 agonist antibody in nonhuman primates., PMID:38372596
Harnessing the potential of CD40 agonism in cancer therapy., PMID:38102001
Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia., PMID:34205588
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer., PMID:34112709
TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy., PMID:34101617
Agonistic CD40 Antibodies in Cancer Treatment., PMID:33804039
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients., PMID:33097612
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)., PMID:31275618
Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters., PMID:28619093
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma., PMID:26386124
Dual Immunotherapies Shrink Melanomas., PMID:25998399
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma., PMID:25252722
Harnessing immune responses in the tumor microenvironment: all signals needed., PMID:24097857
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma., PMID:23983255
Immunotherapy of cancer in 2012., PMID:22576456
CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome., PMID:22459705
The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice., PMID:21479995
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans., PMID:21436454
Poking CD40 for cancer therapy, another example of the Goldilocks effect., PMID:21057206
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors., PMID:20855968
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893., PMID:20842056
Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation., PMID:19906293
An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model., PMID:17444959
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody., PMID:17327609
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
